Effect of transforming growth factor beta 1/Sma-and Mad-related protein signal pathway in diabetic nephropathy and related drugs:a review
10.3867/j.issn.1000-3002.2016.03.013
- VernacularTitle:糖尿病肾病中转化生长因子β1/Sma和Mad相关蛋白信号通路的作用及其相关药物研究进展
- Author:
Huiyu JIA
;
Zhongnan LI
;
Guangliang CHEN
- Publication Type:Journal Article
- Keywords:
diabetic nephropathy;
transforming growth factor-β1;
signaling pathway;
drugs
- From:
Chinese Journal of Pharmacology and Toxicology
2016;30(3):266-271
- CountryChina
- Language:Chinese
-
Abstract:
Transforming growth factor-β1(TGF-β1)has become an important biological marker and therapeutic target of clinical progression of chronic kidney diseases. Sma- and Mad-related protein (Smad)is a downstream signal transduction protein of the TGF-β family. TGF-β1 activates Smad2 and Smad3 before increasing the transcription of connective tissue growth factors in the nucleus. Smad3 promotes mesangial cell proliferation,extracellular matrix accumulation,epithelial-mesenchymal transition, leading to renal fibrosis. However,Smad2 and Smad7 play a negative regulatory role by inhibiting renal fibrosis. TGF-β1 specific inhibitor (SB431542,etc.) has antifibrosis effect,most of which is in the preclinical stage. The drugs on the market that are effective for DN,such as benzodiazepines,atorvastatin, losartan,and pirfenidone,can inhibit the expression of TGF-β1,while tripterygium wilfordii,cordyceps sinensis,and berberine can delay the process of diabetic nephropathy by reducing TGF-β1 levels.
